ensartinib

FDA Drug Profile — ENSACOVE

Drug Details

Generic Name
ensartinib
Brand Names
ENSACOVE
Application Number
NDA218171
Sponsor
Xcovery Holdings, Inc.
NDC Codes
2
Dosage Forms
CAPSULE
Routes
ORAL
Active Ingredients
ENSARTINIB HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] who have not previously received an ALK-inhibitor. ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor. ( 1 , 2.1 )